Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects. Moreover, the combination can reduce the dosage of the opioid needed to be effective, according to a team of pain researchers at Indiana University.

17 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Neuroscientist discovers new mechanism that can reverse chronic pain

It's in the brain where we perceive the unpleasant sensations of pain, and researchers have long been examining how calcium channels in the brain and peripheral nervous system contribute to the development of chronic pain conditions.

4 Sep 2014

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

20 Aug 2014

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

Chronic pain, which persists despite the fact that an injury has healed, can last for many months or years and may affect up to 15 percent of the adult population at any point in time.

13 Aug 2014

New information on limitations and potential for development of transcranial ultrasound therapy

A recent study completed at the University of Eastern Finland provides new information on the limitations and potential new directions for the future development of transcranial ultrasound therapy.

4 Aug 2014

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties.

24 Jul 2014

Choice of HRQoL measure for chronic pain matters

Researchers recommend the use of generic health-related quality of life measures to determine pain-related burden of disease, but consideration needs to be given to which one is used.

21 Jul 2014

Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Glenmark Pharmaceuticals Ltd, a research-driven, global, integrated pharmaceutical company, plans to set up a new manufacturing facility in the US.

17 Jul 2014

Virobay announces closing of expanded Series B second tranche financing

Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million.

16 Jul 2014

Japanese SF-MPQ valid for neuropathic and non-neuropathic pain

Researchers have developed a Japanese translated version of the Short-Form McGill Pain Questionnaire-2 that shows good reliability and validity for discriminating between chronic neuropathic and non-neuropathic pain.

15 Jul 2014

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.

14 Jul 2014

NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

NeuroMetrix, Inc., an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today reported the receipt of marketing certification from Technischer Überwachungs-Verein SÜD Japan Ltd. for NC-stat DPNCheck as a Class II Designated Controlled Medical Device as defined in the technical standards of the Japan Ministry of Health, Labor, and Welfare.

24 Jun 2014

SLU researchers discover pain pathway and potential way to block it

In a recently published study in the Journal of Biological Chemistry, Saint Louis University professor of pharmacological and physiological sciences Daniela Salvemini, Ph.D. describes two discoveries: a molecular pathway by which a painful chemotherapy side effect happens and a drug that may be able to stop it.

24 Jun 2014

American Pain Society, Pain Research Forum provide grant support for PRF's "Papers of the Week"

The American Pain Society announced today it has begun a collaboration with the Pain Research Forum in which APS will provide grant support for PRF's "Papers of the Week" website postings of new papers in pain research, which are published in peer-reviewed journals covering pain, neuroscience and related disciplines.

24 Jun 2014

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain.

23 Jun 2014

International researchers discover genetic component of Idiopathic Generalized Epilepsy

An international team of researchers has discovered a significant genetic component of Idiopathic Generalized Epilepsy (IGE), the most common form of epilepsy.

17 Jun 2014

Discovery may lead to relief for victims of range of neurological disorders

University of Toronto biologists leading an investigation into the cells that regulate proper brain function, have identified and located the key players whose actions contribute to afflictions such as epilepsy and schizophrenia.

6 Jun 2014

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

Neuropathic Pain News and Research

Further Reading

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Neuroscientist discovers new mechanism that can reverse chronic pain

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

New information on limitations and potential for development of transcranial ultrasound therapy

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Choice of HRQoL measure for chronic pain matters

Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Virobay announces closing of expanded Series B second tranche financing

Japanese SF-MPQ valid for neuropathic and non-neuropathic pain

Researchers create combination drug that controls both tumor growth and metastasis

NeuroMetrix receives marketing certification from TÜV SÜD Japan for NC-stat DPNCheck

SLU researchers discover pain pathway and potential way to block it

American Pain Society, Pain Research Forum provide grant support for PRF's "Papers of the Week"

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

International researchers discover genetic component of Idiopathic Generalized Epilepsy

Discovery may lead to relief for victims of range of neurological disorders

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News